Tesa10+ip5 15mg*10vials
A 15mg total blend per vial containing Tesamorelin 10mg plus Ipamorelin 5mg, supplied as 10 vials. For research use only (RUO); not for human or veterinary use.
Out of stock
Tesamorelin 10mg + Ipamorelin 5mg, 15mg total, 10 vials Product Description
This fixed formulation is displayed as tesamorelin 10mg plus ipamorelin 5mg per vial, totaling 15mg per vial, in a 10-vial pack. The 2:1 mass ratio is a defining catalog attribute. Tesamorelin is a GHRH analog, whereas ipamorelin is a distinct pentapeptide secretagogue-receptor agonist; the two identities must not be collapsed.
The title does not verify either sequence, chemical form, per-component content, mixture homogeneity, compatibility, or stability. Its language, specifications, and testing statements cannot be transferred to the requested 15mg formulation.
For research catalog purposes, this item should be framed as a precisely named but analytically unverified blend. Ingredient publications may help researchers understand why separate controls are necessary, but they do not validate the combination. A robust study design would distinguish ingredient-specific effects from mixture-associated observations and would document the actual component identities and measured content of the lot before interpreting data. No certificate values are available in this draft, and no statement about purity, sterility, endotoxin, stability, or analytical performance is implied. The item is for research use only and is not for human or veterinary use. Qualified laboratories should base protocol decisions on their own requirements, the verified identity of the received material, and lot-specific records rather than on a retail family name. Catalog inclusion does not establish fitness for a particular method. Receiving records, chain of custody, reference standards, and acceptance criteria should be defined by the laboratory and documented independently for every lot and presentation.
Research Material Profile
Tesamorelin 10mg + Ipamorelin 5mg, 15mg total, 10 vials Research
Tesamorelin-only clinical research
PMID 25038357 reports a randomized controlled study of tesamorelin alone in a defined HIV-positive adult cohort, with prespecified imaging and metabolic measurements. The study did not include ipamorelin and did not evaluate a fixed 2:1 blend. Its observations are therefore limited to the characterized tesamorelin material, selected population, protocol, and endpoints. They should not be transformed into claims for this product or generalized into wellness, physique, or treatment language. The paper provides ingredient-level research context only. It does not establish the tesamorelin sequence, chemical form, or 10mg content in these vials, and it says nothing about compatibility with ipamorelin. Using the source responsibly means keeping the clinical record separate from product documentation and explicitly noting that the commercial formulation has not been studied in that trial. Across interpretations, the publication supports only its reported material and measurements; it does not supply lot-level identity, composition, or quality evidence for this catalog presentation. (PubMed 25038357).
Ipamorelin preclinical research
PMID 9849822 characterizes ipamorelin as a defined pentapeptide and examines secretagogue-receptor pharmacology in cultured rat pituitary cells and animal models. Those results apply to ipamorelin alone under the reported conditions. The source does not test tesamorelin, a two-component formulation, the 5mg portion of this vial, or a ten-vial commercial pack. It can support the ingredient name and model-specific scientific context, but not mixture behavior, synergy, stability, combined activity, or lot quality. Any laboratory comparison should use an authenticated ipamorelin control and a separate tesamorelin control if the research question requires attribution. Without component-resolved analytical documentation, an observation from the blend cannot automatically be assigned to either named peptide. The citation supplies no product-level assurance. Across interpretations, the publication supports only its reported material and measurements; it does not supply lot-level identity, composition, or quality evidence for this catalog presentation. (PubMed 9849822).
Exact-formulation evidence gap
No cited paper evaluates tesamorelin 10mg plus ipamorelin 5mg as this exact 15mg-per-vial, 10-vial formulation. Ingredient studies cannot establish how the components behave when combined, whether the mixture remains homogeneous, or whether either component matches its stated content. For that reason, it serves only as a page-layout and naming reference. Research conclusions should be limited to measured endpoints using a documented lot, with blend identity treated independently from ingredient identity. The arithmetic total and ratio come from the catalog title; they are not certificate results or analytical findings. Across interpretations, the publication supports only its reported material and measurements; it does not supply lot-level identity, composition, or quality evidence for this catalog presentation. (PubMed 25038357 · PubMed 9849822).
Evidence Boundaries
The cited publications describe defined study materials in particular biochemical, cell, animal, or controlled human research settings. They do not authenticate this catalog item, transfer analytical specifications to it, or establish that a nominally similar retail product is equivalent. Model observations must remain attached to the reported species, preparation, protocol, and endpoints. Where the title leaves sequence, chemical form, processing state, physical unit, formulation, or pack details unresolved, this draft leaves them unresolved as well. No purity percentage, sterility status, endotoxin result, stability period, or content assay is inferred. Any stronger conclusion requires lot-specific documentation and, where relevant, direct testing of the exact formulation.
Tesamorelin 10mg + Ipamorelin 5mg, 15mg total, 10 vials References
8 curated medical and scientific references used for identity, mechanism, model, and assay context.
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334. PMID:25038357.
Tesamorelin randomized clinical research · Randomized controlled study in adults with HIV and abdominal fat accumulation using imaging and metabolic endpoints.
View research source - Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. doi:10.1097/qai.0b013e3181cbdaff. PMID:20101189.
Tesamorelin controlled trial with extension · Randomized placebo-controlled human study and safety extension in a defined HIV population.
View research source - Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490. PMID:20554713.
Pooled tesamorelin phase 3 analyses · Pooled controlled human studies with extension data in a defined HIV population.
View research source - Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.
Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. doi:10.1210/jc.2010-1587. PMID:20943777.
GHRH analogue and endogenous GH pulsatility · Controlled human physiology study in healthy men.
View research source - Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/nejmoa072375. PMID:18057338.
Growth-hormone-releasing factor research in HIV · Randomized controlled human study of tesamorelin/TH9507-related GHRF material.
View research source - Ipamorelin, the first selective growth hormone secretagogue.
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID:9849822.
Ipamorelin identity and secretagogue pharmacology · Isolated rat pituitary-cell assays and rat experiments.
View research source - Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
Gobburu JV, Agersø H, Jusko WJ, Ynddal L Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi:10.1023/a:1018955126402. PMID:10496658.
Ipamorelin PK/PD modeling · Controlled human volunteer study with plasma concentration and timed GH measurements.
View research source - Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.
Johansen PB, Hansen KT, Andersen JV, Johansen NL Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083-1092. doi:10.1080/004982598238976. PMID:9879640.
Comparative disposition of peptidyl GH secretagogues · Animal pharmacokinetic experiments comparing ipamorelin and other defined secretagogues.
View research source